State of New Jersey Common Pension Fund D Purchases 1,149 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

State of New Jersey Common Pension Fund D lifted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,822 shares of the biopharmaceutical company’s stock after purchasing an additional 1,149 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Intra-Cellular Therapies were worth $3,075,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies in the third quarter valued at approximately $32,000. GAMMA Investing LLC increased its position in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Intra-Cellular Therapies during the third quarter worth $74,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the third quarter worth $97,000. Finally, Quarry LP increased its position in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,300 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ITCI shares. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. JPMorgan Chase & Co. boosted their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Finally, Piper Sandler reissued a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $103.62.

Intra-Cellular Therapies Stock Down 0.0 %

ITCI stock opened at $128.54 on Friday. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.77. The company’s 50-day simple moving average is $109.36 and its 200-day simple moving average is $89.29. The firm has a market cap of $13.67 billion, a P/E ratio of -147.75 and a beta of 0.72.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.